Arvinas, Inc.

Citigroup raised its price target to $24.00 with a "buy" rating, and both Stephens and Barclays issued "overweight" ratings with targets up to $20.00, suggesting meaningful upside from current trading levels near $8.00–$10.00. Eight analysts hold Buy ratings, reflecting confidence in Arvinas' long-term value.

Wall Street Zen downgraded Arvinas to "strong sell," while the consensus rating sits at "Hold" with an average price target of only $15.42 — still reflecting deep uncertainty. The company missed quarterly revenue expectations of $16.61M, posting only $15.60M, and analysts forecast a loss of -$2.82 EPS for the current year.

The 2026 revenue forecast for Arvinas was revised sharply upward, from $93.2M to $122.4M, representing a significant upgrade driven by 16 analysts. This upward revision suggests growing confidence in the company's ability to generate meaningful revenue from its targeted protein degradation pipeline.

Despite the upgraded revenue forecast, Arvinas continues to trade at a market cap of just $646M and recently missed quarterly revenue estimates. With a projected EPS of -$2.82, the company remains unprofitable, raising concerns about the pace and sustainability of its commercial ramp-up relative to its cash burn.

Arvinas is a pioneer in targeted protein degradation (PROTAC technology), a differentiated therapeutic modality with few direct competitors. Analyst upgrades from firms like Zacks (raised to "hold") and sustained "overweight" ratings from Barclays and Stephens indicate confidence in the clinical promise and differentiation of its pipeline.

The broader biotech landscape highlights the extreme binary risk of drug development — a single failed trial result can erase billions in market value overnight. Arvinas, still pre-profitability and reliant on pipeline execution, faces acute regulatory and clinical risk, as reflected in the "strong sell" downgrade and persistent sell-side skepticism.